ישראל -
עברית -
Ministry of Health
גמזר 1 גרם
eli lilly israel ltd - gemcitabine as hydrochloride - אבקה מיובשת בהקפאה להכנת תרכיז לאינפוזיה - gemcitabine as hydrochloride 1 g/vial - pyrimidine analogues - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy.prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.
ישראל -
עברית -
Ministry of Health
גמזר 1 גרם
eli lilly israel ltd - gemcitabine as hydrochloride - אבקה מיובשת בהקפאה להכנת תרכיז לאינפוזיה - gemcitabine as hydrochloride 1 g/vial - pyrimidine analogues - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy.prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.
ישראל -
עברית -
Ministry of Health
אפיפואם
megapharm ltd - hydrocortisone acetate; pramocaine hydrochloride - קצף - pramocaine hydrochloride 0.9363 %w/w; hydrocortisone acetate 0.9363 %w/w - relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
ישראל -
עברית -
Ministry of Health
קפסיטבין אינובמד 500 מג
inovamed ltd - capecitabine - טבליות מצופות פילם - capecitabine 500 mg - capecitabine
ישראל -
עברית -
Ministry of Health
קפסיטבין אינובמד 500 מג
inovamed ltd - capecitabine - טבליות מצופות פילם - capecitabine 500 mg - capecitabine
ישראל -
עברית -
Ministry of Health
קפציטבין טבע 150 מג
abic marketing ltd, israel - capecitabine - טבליות מצופות פילם - capecitabine 150 mg - capecitabine
ישראל -
עברית -
Ministry of Health
קפציטבין טבע 500 מג
abic marketing ltd, israel - capecitabine - טבליות מצופות פילם - capecitabine 500 mg - capecitabine
ישראל -
עברית -
Ministry of Health
אווסטין
roche pharmaceuticals (israel) ltd - bevacizumab - תרכיז להכנת תמיסה לאינפוזיה - bevacizumab 25 mg/ml - bevacizumab - bevacizumab - avastin in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of patients with metastatic carcinoma of the colon or rectum.avastin in addition to platinum - based chemotherapy is indicated for first - line treatment of patients with unresectable advanced metastatic or recurrent non- small cell lung cancer other than predominantly squamous cell histology. avastin in combination with interferon alfa-2a is indicated for first line treatment of patients with advanced and /or metastatic renal cell cancer. avastin in combination with paclitaxel is indicated for first-line treatment of patients with metastatic breast cancer.avastin as asingle agent, is indicated for the treatment of glioblastoma in patients with progressive disease following prior therapy.avastin, in combination with carboplatin and paclitaxel, is indicated for the front-line treatment of advanced (figo stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are at hig